Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Angion Biomedica stock | $15.44

Learn how to easily invest in Angion Biomedica stock.

Angion Biomedica Corp
-$0.35 (-3.03%)

Angion Biomedica Corp is a biotechnology business based in the US. Angion Biomedica shares (ANGN) are listed on the NASDAQ and all prices are listed in US Dollars. Angion Biomedica employs 66 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Angion Biomedica

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Angion Biomedica stock price (NASDAQ: ANGN)

Use our graph to track the performance of ANGN stocks over time.

Angion Biomedica shares at a glance

Information last updated 2021-07-28.
Latest market close$15.44
52-week range$10.50 - $26.30
50-day moving average $12.33
200-day moving average $15.49
Wall St. target price$59.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Angion Biomedica shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Angion Biomedica stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Angion Biomedica price performance over time

Historical closes compared with the close of $15.44 from 2021-05-28

1 week (2021-07-26) N/A
1 month (2021-07-06) 36.76%
3 months (2021-05-06) 7.82%
6 months (2021-02-02) N/A
1 year (2020-08-02) N/A
2 years (2019-08-02) N/A
3 years (2018-08-02) N/A
5 years (2016-08-02) N/A

Angion Biomedica financials

Revenue TTM $2.4 million
Gross profit TTM $-37,287,000
Return on assets TTM -116.52%
Return on equity TTM 0%
Profit margin 0%
Book value $3.12
Market capitalisation $324.2 million

TTM: trailing 12 months

Shorting Angion Biomedica shares

There are currently 300,721 Angion Biomedica shares held short by investors – that's known as Angion Biomedica's "short interest". This figure is 11.3% up from 270,103 last month.

There are a few different ways that this level of interest in shorting Angion Biomedica shares can be evaluated.

Angion Biomedica's "short interest ratio" (SIR)

Angion Biomedica's "short interest ratio" (SIR) is the quantity of Angion Biomedica shares currently shorted divided by the average quantity of Angion Biomedica shares traded daily (recently around 102635.15358362). Angion Biomedica's SIR currently stands at 2.93. In other words for every 100,000 Angion Biomedica shares traded daily on the market, roughly 2930 shares are currently held short.

To gain some more context, you can compare Angion Biomedica's short interest ratio against those of similar companies.

However Angion Biomedica's short interest can also be evaluated against the total number of Angion Biomedica shares, or, against the total number of tradable Angion Biomedica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Angion Biomedica's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Angion Biomedica shares in existence, roughly 10 shares are currently held short) or 0.0137% of the tradable shares (for every 100,000 tradable Angion Biomedica shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Angion Biomedica.

Find out more about how you can short Angion Biomedica stock.

Angion Biomedica share dividends

We're not expecting Angion Biomedica to pay a dividend over the next 12 months.

Angion Biomedica overview

Angion Biomedica Corp. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York. .

Frequently asked questions

What percentage of Angion Biomedica is owned by insiders or institutions?
Currently 26.57% of Angion Biomedica shares are held by insiders and 18.262% by institutions.
How many people work for Angion Biomedica?
Latest data suggests 66 work at Angion Biomedica.
When does the fiscal year end for Angion Biomedica?
Angion Biomedica's fiscal year ends in December.
Where is Angion Biomedica based?
Angion Biomedica's address is: 51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site